Martin Auster
Stock Analyst at Raymond James
(4.23)
# 417
Out of 5,240 analysts
56
Total ratings
60.47%
Success rate
14.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Initiates: Strong Buy | $6 | $2.31 | +159.74% | 1 | Apr 14, 2026 | |
| SYRE Spyre Therapeutics | Initiates: Strong Buy | $80 | $76.31 | +4.84% | 1 | Apr 14, 2026 | |
| EVMN Evommune | Initiates: Strong Buy | $40 | $23.29 | +71.75% | 1 | Jan 8, 2026 | |
| SEPN Septerna | Initiates: Strong Buy | $38 | $24.75 | +53.54% | 1 | Dec 19, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Outperform | $69 → $71 | $68.61 | +3.48% | 2 | Oct 30, 2025 | |
| RNA Atrium Therapeutics | Downgrades: Market Perform | n/a | $13.30 | - | 2 | Oct 27, 2025 | |
| IRON Disc Medicine | Maintains: Strong Buy | $89 → $108 | $70.11 | +54.04% | 1 | Oct 17, 2025 | |
| ASND Ascendis Pharma | Initiates: Strong Buy | $271 | $243.58 | +11.26% | 1 | Oct 17, 2025 | |
| DYN Dyne Therapeutics | Upgrades: Strong Buy | $31 → $35 | $18.44 | +89.80% | 2 | Aug 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $291.48 | +45.46% | 2 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $120 | $53.55 | +124.09% | 7 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $99 → $105 | $26.46 | +296.83% | 7 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $26 | $7.25 | +258.62% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $120 | $7.38 | +1,526.02% | 4 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $58 | $31.70 | +82.97% | 3 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $169 → $196 | $579.54 | -66.18% | 4 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $98 | $2.03 | +4,727.59% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $117.99 | -49.15% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $50.17 | +29.56% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $18.84 | +287.47% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $29.17 | +167.40% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.12 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $9.48 | +353.59% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $14.28 | +47.06% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $62.69 | -74.48% | 1 | May 7, 2020 |
Equillium
Apr 14, 2026
Initiates: Strong Buy
Price Target: $6
Current: $2.31
Upside: +159.74%
Spyre Therapeutics
Apr 14, 2026
Initiates: Strong Buy
Price Target: $80
Current: $76.31
Upside: +4.84%
Evommune
Jan 8, 2026
Initiates: Strong Buy
Price Target: $40
Current: $23.29
Upside: +71.75%
Septerna
Dec 19, 2025
Initiates: Strong Buy
Price Target: $38
Current: $24.75
Upside: +53.54%
BridgeBio Pharma
Oct 30, 2025
Reiterates: Outperform
Price Target: $69 → $71
Current: $68.61
Upside: +3.48%
Atrium Therapeutics
Oct 27, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $13.30
Upside: -
Disc Medicine
Oct 17, 2025
Maintains: Strong Buy
Price Target: $89 → $108
Current: $70.11
Upside: +54.04%
Ascendis Pharma
Oct 17, 2025
Initiates: Strong Buy
Price Target: $271
Current: $243.58
Upside: +11.26%
Dyne Therapeutics
Aug 25, 2025
Upgrades: Strong Buy
Price Target: $31 → $35
Current: $18.44
Upside: +89.80%
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $291.48
Upside: +45.46%
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $53.55
Upside: +124.09%
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $26.46
Upside: +296.83%
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $7.25
Upside: +258.62%
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $7.38
Upside: +1,526.02%
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $31.70
Upside: +82.97%
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $579.54
Upside: -66.18%
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $2.03
Upside: +4,727.59%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $117.99
Upside: -49.15%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $50.17
Upside: +29.56%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $18.84
Upside: +287.47%
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $29.17
Upside: +167.40%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $3.12
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $9.48
Upside: +353.59%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $14.28
Upside: +47.06%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $62.69
Upside: -74.48%